Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
“We are trying to evaluate the ctDNA role in prognostication as well,” says Chinmay Jani, MD.
The BLA submission is supported by findings from the phase 3 ZIRCON trial, which demonstrated high specificity and sensitivity of TLX250-CDx for PET/CT imaging of ccRCC.
David A. Braun, MD, PhD, highlights the developing role of T-cell therapies in RCC and looks toward the horizon for other advances.
Manmeet Ahluwalia, MD, MBA, FASCO, discusses findings from a National Cancer Database analysis on treatment outcomes of brain metastases from primary RCC.
The following is a summary of “Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma,” published in the April 2024 issue of Nephrology by...
Benjamin L. Maughan, MD, PharmD, highlights key studies presented at the 2024 ASCO Annual Meeting regarding biomarkers and the evolution of first-line treatments in renal cell carcinoma.
Accounting for 4% of all cases, kidney cancer is currently the sixth most common cancer diagnosed in the UK
Renal cell carcinoma (RCC) is a malignant tumor with high incidence in adult kidney. Long non-coding RNAs (lncRNAs) have recently been recognized as important regulators in the development of RCC. However, whether lncRNA SNHG1 is associated with RCC progression remains to be elucidated. Here, ...
“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Dr. Priya Hays, PhD, CEO and Science Writer at Hays Documentation Specialists, LLC, guides us through the world of personalized cancer medicines.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.